Yan Xu,Weitao Yang,Zhuoyao Wu,Hui Wang,Tianming Cui,Weiwei Zeng,Yanjing Yun,Bingbo Zhang
Effective monitoring of gastric fluid pH is crucial for diagnosing gastric diseases and evaluating anti-gastric-acid therapies. The invasiveness and low patient compliance with traditional gastric fluid aspiration methods highlight the need of a non-invasive, real-time technique for in situ gastric pH monitoring. This study introduces a novel chromium (Cr)-based magnetic resonance probe, Cr(OH) 3 @HSA, specifically designed for pH-sensitive gastric imaging. Synthesized via an albumin-mediated biomimetic mineralization process, Cr(OH) 3 @HSA possesses an amorphous structure that facilitates the sensitive release of paramagnetic Cr(III) ions in acidic environments. This release substantially decreases the longitudinal relaxation time of surrounding hydrogen protons, as demonstrated by an 18.29-fold increase in the longitudinal relaxation rate from pH 6.5 to pH 1.0. In vivo experiments show that Cr(OH) 3 @HSA accurately detects abnormal gastric pH levels and evaluates the efficacy of gastric antiacids, surpassing the performance of the conventional “always-on” contrast agent, Magnevist®. Notably, our research reveals that chromium picolinate, a common dietary supplement for diabetes, generates a “turn-on” signal in the gastrointestinal tract, suggesting potential MR signal interference in diabetic patients. Consequently, we recommend that diabetic patients avoid chromium-based dietary supplements prior to MRI procedures to prevent Cr(III)-induced signal alterations.
Probiotics are closely related to human health. However, it is hard to find an appropriate disintegration mode for encapsulation to balance the survival, release, and adhesion of probiotics simultaneously during the current colon-targeted oral delivery, which leads to limited colonization. In this study, an enzyme-triggered fuse-like microcapsule is constructed using alginate and protamine via the electrostatic droplet combined with the layer by layer self-assembly. The multilayer microcapsule can protect the probiotics in the stomach and disintegrate layer by layer under the catalysis of trypsin in the intestine. The formulation with two protamine layers showed the best protection for Escherichia coli MG1655 (EM) during the oral delivery; as well the minimal release at the gastric pH value but a burst release after 1 h at the intestinal pH value. In particular, the adhesion strength of EM is improved with the increase of the layer number. In vivo experiments demonstrate that the EM enters into the stationary phase within 12 h in the colon. Moreover, the blood biochemistry and histological analysis demonstrates the safety of the microcapsule formulation. It can be concluded that this microcapsule can help the probiotics survive during the delivery, then release and colonize in the colon.
危险品化学品经营许可证（带存储）